Biotage AB
STO:BIOT

Watchlist Manager
Biotage AB Logo
Biotage AB
STO:BIOT
Watchlist
Price: 155 SEK 2.58% Market Closed
Market Cap: 12.3B SEK
Have any thoughts about
Biotage AB?
Write Note

Biotage AB
Long-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Biotage AB
Long-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
Biotage AB
STO:BIOT
Long-Term Investments
kr25m
CAGR 3-Years
28%
CAGR 5-Years
8%
CAGR 10-Years
28%
AddLife AB
STO:ALIF B
Long-Term Investments
kr9m
CAGR 3-Years
1%
CAGR 5-Years
-28%
CAGR 10-Years
N/A
BICO Group AB
STO:BICO
Long-Term Investments
kr45.5m
CAGR 3-Years
52%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genovis AB
STO:GENO
Long-Term Investments
kr90k
CAGR 3-Years
-75%
CAGR 5-Years
-45%
CAGR 10-Years
-31%
MedCap AB (publ)
STO:MCAP
Long-Term Investments
kr500k
CAGR 3-Years
-44%
CAGR 5-Years
-22%
CAGR 10-Years
-9%
M
Magle Chemoswed Holding AB
STO:MAGLE
Long-Term Investments
kr55k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Biotage AB
Glance View

Market Cap
12.4B SEK
Industry
Life Sciences Tools & Services

Biotage AB engages in the provision of separation and synthesis technology solutions. The company is headquartered in Uppsala, Uppsala and currently employs 497 full-time employees. The company went IPO on 2000-06-30. Its customers include pharmaceutical and biotechnology companies, companies within the food industry and academic institutions. The firm offers systems and services within three areas: analytical chemistry, organic chemistry and industrial resins. Biotage’s offering within analytical chemistry consists of consumables with related applications to extract selected substances from various types of samples. The Company’s offering within organic chemistry includes products for pharmaceutical development based on both small molecules and peptides and its offering within industrial resins is composed of polymer-based resins and research services that lead to the development and manufacture of polymer-based materials. As of December 31, 2013, the Company operated 12 wholly owned subsidiaries worldwide.

BIOT Intrinsic Value
196.81 SEK
Undervaluation 21%
Intrinsic Value
Price

See Also

What is Biotage AB's Long-Term Investments?
Long-Term Investments
25m SEK

Based on the financial report for Sep 30, 2024, Biotage AB's Long-Term Investments amounts to 25m SEK.

What is Biotage AB's Long-Term Investments growth rate?
Long-Term Investments CAGR 10Y
28%

Over the last year, the Long-Term Investments growth was 32%. The average annual Long-Term Investments growth rates for Biotage AB have been 28% over the past three years , 8% over the past five years , and 28% over the past ten years .

Back to Top